

List of Figures and Tables

Figures		Page No.
General Introduction		
Fig. 1	Schematic representation of circadian rhythm operating in the biological system.	4
Fig. 2	Core and peripheral circadian clocks of the body and factors manifesting alterations.	6
Fig. 3	Pathological implications of chronodisruption.	13
Fig. 4	The diagram depicts cardiovascular disorders and the potential risk factors.	15
Fig.5	The global burden of cardiovascular diseases marked in national and sub-national locations.	16
Fig. 6	Prevalence of cardiovascular diseases in India.	17
Fig. 7	Schematic representation of arterial status at different stages of atherogenic progression.	19
Fig. 8	Diagrammatic representation of arterial positioning and related acute or chronic pathological conditions.	19
Fig. 9	Physiological composition of Low-Density Lipoprotein (LDL) particle.	22
Fig. 10	Physiological status of oxidized LDL (ox-LDL) and its positioning in atheromatous plaque.	22
Fig. 11	physiological composition of High-Density Lipoprotein (LDL) particle.	24

Fig. 12a	Schematic diagram of the physiological functions of carbon monoxide.	38
Fig. 12b	Schematic diagram of the effects of carbon monoxide on the cardiovascular system.	41
Fig. 13	Pictorial representation of canonical and non-canonical miRNA biogenesis pathways operating in biological systems.	46
Fig. 14	Schematic representation of various miRNAs functional in different cells in atherogenic milieu.	49

Material and Methods

Fig. M1	Photoperiodic regimen followed for instilling chronodisruption in male C57BL/6J mice.	55
Fig. M2	Microscopic images of THP-1 cells differentiated to MDMs at different concentrations of PMA.	62
Fig. M3	Assessing methylation pattern in the promoter of miR34a-5p using MSP Assay.	68

Chapter 1

Fig. 1.1	miRNA complementary to 3'UTR seed sequence of <i>Clock</i> gene in human and mice.	93
Fig. 1.2	Venn diagram representing number of unique and common <i>Clock</i> associated miRNAs shared between human and mice.	94
Fig. 1.3	Potential gene targets and evolutionary conservation of miR34a-5p.	96
Fig. 1.4	Pathological association of miR34a-5p.	97

Chapter 2

Fig. 2.1	Altered <i>Clock</i> gene expression in thoracic aorta of C57BL/6J mice.	113
Fig. 2.2	Expression and epigenetic modification in the promoter region of miR34a-5p.	114
Fig. 2.3	Circadian rhythm of miR34a-5p and its target genes in thoracic aorta of C57BL/6J mice.	116
Fig. 2.4	Physiological traits of C57BL/6J mice.	117
Fig. 2.5	Food and water intake of C57BL/6J mice.	118
Fig. 2.6	Serum Lipid profile of C57BL/6J mice.	119
Fig. 2.7	Histomorphological analysis of thoracic aortae of C57BL/6J mice.	120
Fig. 2.8	Assessment of fibrillar content of the thoracic aortae of C57BL/6J mice.	121
Fig. 2.9	Quantification of pro-atherogenic genes in thoracic aortae.	122
Fig. 2.10	Circadian rhythm of miR34a-5p and its target genes in HUVECs.	124
Fig. 2.11	Assessing Clock gene interaction in HUVECs with elevated miR34a-5p.	125
Fig. 2.12	Immunocytochemical analysis for CLOCK gene expression	126
Fig. 2.13	Clock – miR34a-5p interaction	127

Chapter 3

Fig. 3.1	Network diagram of carbon monoxide (CO) association and regulation of circadian clock genes.	146
Fig. 3.2	<i>En face</i> assay of thoracic aortae of Sprague Dawley (SD) rats.	147
Fig. 3.3.1	Assessing pro-atherogenic changes in thoracic aortae of SD rats.	148

Fig. 3.1.2	Assessing pro-atherogenic changes in thoracic aortae of SD rats treated with iCORM-A1 (inactive CORM-A1).	149
Fig. 3.4	Serum profile of Sprague Dawley rats fed on atherogenic diet only/or treated with CORM-A1.	150
Fig. 3.5	Cytotoxicity of CORM-A1 evaluated at different doses in HUVEC and MDMs.	151
Fig. 3.6	Physiological assessment of CORM-A1 on expression of miR34a-5p and its gene target SIRT1.	152
Fig. 3.7	Atherogenic model development in HUVEC and MDMs	153
Fig. 3.8	Assessing levels of miR34a-5p in all the experimental models (HUVEC, MDMs and aorate of SD rats).	154
Fig. 3.9	miR34a-5p transcription inhibitors Zeb-1, Snail and Stat3 were quantified in HUVEC, MDMs and thoracic aortae.	155
Fig. 3.10	Assessment of epigenetic modification in disease condition and CORM-A1 treated HUVEC and MDMs by MSP assay.	156
Fig. 3.11	Association of carbon monoxide molecule with miR34a-5p transcription factors P53 and NF- κ B.	159

Chapter 4a

Fig. 4a.1	mRNA quantification of <i>KLF4</i> gene.	171
Fig. 4a.2	KLF4 interaction with miR34a-5p.	173
Fig. 4a.3	Transcriptomal quantification of <i>NF-κB</i> gene.	174
Fig. 4a.4	Thoracic aortae harvested from Sprague Dawley rats assessed for atherogenic changes by Immunohistochemical (IHC) analysis	175

Fig. 4a.5	Endothelial cell activation and monocyte adhesion assessed with adhesion assay.	176
Fig. 4a.6	Transcriptomal quantification of <i>ICAM1</i> , <i>VCAM1</i> and <i>MCP-1</i> genes in thoracic aortae of SD rats, HUVEC and MDMs.	177
Fig. 4a.7	Transcriptomal quantification of TNF α , iNOS and Arg1 genes in thoracic aortae of SD rats, HUVEC and MDMs.	178

Chapter 4b

Fig. 4b.1	Mitochondrial DNA was quantification in all the experimental models.	192
Fig. 4b.2	MitoTracker Red staining for mitochondrial mass assessment in HUVEC and MDMs.	193
Fig. 4b.3	miR34a-5p antagomiR in atherogenic model system, comparison with CORM-A1.	196
Fig. 4b.4	Transcriptional quantification of mitochondrial biogenesis genes HUVEC, MDMs and thoracic aorta.	197
Fig. 4b.5	Mitochondrial membrane potential assessed with JC1 staining in HUVEC and MDMs.	198
Fig. 4b.6	Immunohistochemical analysis for HSP60.	199
Fig. 4b.7	Assessment of mitochondrial antioxidant genes TrxR2 and SOD2.	200
Fig. 4b.8	Cellular redox status assessed by DCFDA staining in HUVEC and MDMs.	201
Fig. 4b.9	ATP quantification in HUVEC and MDMs and thoracic aortae of SD rats.	202

Fig. 4b.10 Assessing mitochondrial function with OCR and ECAR value **204**
analysis analyzed with Seahorse assay in HUVEC.

Fig. 4b.11 Assessing mitochondrial function with OCR and ECAR value **206**
analysis analyzed with Seahorse assay in MDMs.

Concise Summary

Fig. S1 Diagrammatic representation of miR34a-5p – Clock interaction **216**
and circadian rhythms.

Fig. S2 Diagrammatic representation of miR34a-5p status in **223**
atherosclerosis and CORM-A1 mediated miRNA lowering.

Tables	Page No.
---------------	-----------------

General Introduction

Table 1	Metabolic phenotypes observed after clock gene disruption.	9
Table 2	Diagnostic tests for atherosclerosis.	29
Table 3	miRNAs reported to be functional in atherogenic pathophysiology.	50

Materials and Methods

Table M1	List of mice primers for qPCR.	76
Table M2	List of human primers for qPCR.	77
Table M3	List of rat primers for qPCR.	79
Table M4	List of primers used for Methylation Specific PCR Assay.	80
Table M5	List of primers for mtDNA Assay.	81

Chapter 1

Table 1.1	Information on miR34a-5p – CLOCK docking, studied using computational algorithms in human, mice, and rats.	96
------------------	--	-----------

Chapter 3

Table 3.1	Docking score and interactions of CO with target proteins NF-κB and P53.	160
Table 3.2	Free energy calculations (MM-GBSA) of CO bound to NF-kb and p53.	160

Chapter 4a

Table 4a.1	Information of miR34a-5p – KLF4 docking, studied using computational algorithms in human, mice, and rats.	172
-------------------	---	------------